1 documents found
Information × Registration Number 0216U000338, 0113U001201 , R & D reports Title To develope adequate anemia treatment in CKD-VDst. patients with pharmaco-economy validation. popup.stage_title Head Kolesnyk M.O., Registration Date 29-01-2016 Organization Institute of Nephrology Ukraine Academi Science of Medicine popup.description2 Determined that dialysis treatment influence on total dose erythropoiesis stimulating means to reach the target hemoglobin level. It is established that the treatment associated with HDF using less total dose erythropoietin-beta ((100 ± 62,3) mg vs (57,7 ± 18,64) mg, p = 0.02) than darbopoetyn ((122,14 ± 17.92) mg vs (85,88 ± 14,35) microgram, p = 0.049). Proven farmakoekonomic application passes PEGerythropoietin beta versus darbepoetin. Found that type of erytropoetin for correction of anemia in dialysis patients affect indicators of oxidative damage to red blood cells and integrated assessment of the proposed method of resistance of erythrocyte membrane offer. Product Description popup.authors Бездєтко Н.В. Бурдейна О.В. Бусигіна Ю.С. Епіфанов В.М. Колесник М.О. Король Л.В. Малашевська Н.М. Мигаль Л.Я. Перейма О.Ю. Попова О.С. Савченко С.М. popup.nrat_date 2020-04-02 Close
R & D report
To develope adequate anemia treatment in CKD-VDst. patients with pharmaco-economy validation.
Head: Kolesnyk M.O.. To develope adequate anemia treatment in CKD-VDst. patients with pharmaco-economy validation.. (popup.stage: ). Institute of Nephrology Ukraine Academi Science of Medicine. № 0216U000338
1 documents found

Updated: 2026-03-24


Роздрукувати цю сторінку